Advertisement

PARP Inhibitors for Cancer Therapy

  • Nicola J. Curtin
  • Ricky A. Sharma

Part of the Cancer Drug Discovery and Development book series (CDD&D, volume 83)

Table of contents

  1. Front Matter
    Pages i-xix
  2. What PARP is and What it Does

    1. Front Matter
      Pages 1-1
    2. Takashi Sugimura, Sydney Shall
      Pages 3-13
    3. Eléa Héberlé, Jean-Christophe Amé, Giuditta Illuzzi, Françoise Dantzer, Valérie Schreiber
      Pages 15-46
    4. Stuart L. Rulten, Françoise Dantzer, Keith W. Caldecott
      Pages 47-78
    5. Susan Smith
      Pages 79-97
    6. Junhui Wang, Akira Sato, Hiroaki Fujimori, Yoshio Miki, Mitsuko Masutani
      Pages 99-124
    7. Aswin Mangerich, Alexander Bürkle
      Pages 125-179
  3. NAD Catalysis and the Identification of Inhibitors

    1. Front Matter
      Pages 181-181
    2. Stacie S. Canan
      Pages 205-221
  4. Chemo- and Radiosensitisation in Vitro and in Vivo

    1. Front Matter
      Pages 223-223
    2. David R. Shalinsky, Cherrie K. Donawho, Gerrit Los, Joann P. Palma
      Pages 225-260
    3. Charles Fouillade, Alexis Fouquin, Mohammed-Tayyib Boudra, Vincent Favaudon, Vincent Pennaneach, Janet Hall
      Pages 275-297
    4. Cian M. McCrudden, Kaye J. Williams
      Pages 299-311
  5. Synthetic Lethality

    1. Front Matter
      Pages 313-313
    2. Helen E. Bryant, Sydney Shall
      Pages 315-344
    3. Katarzyna B. Leszczynska, Nadya Temper, Robert G. Bristow, Ester M. Hammond
      Pages 345-361
    4. Naoyuki Okita, Atsushi Shibata
      Pages 363-379
    5. Liam Cornell, Neil Johnson, Geoffrey I. Shapiro
      Pages 413-430
    6. Kiranjit K. Dhillon, Toshiyasu Taniguchi
      Pages 431-452
    7. Guotai Xu, Jos Jonkers, Sven Rottenberg
      Pages 453-471
  6. Clinical Status

    1. Front Matter
      Pages 473-473
    2. Ruth Plummer, Yvette Drew
      Pages 475-486
    3. Sheena Irshad, Andrew Tutt
      Pages 487-510
    4. Ashley K. Clift, Nicholas Coupe, Mark R. Middleton
      Pages 511-531
    5. Ross Carruthers, Anthony J Chalmers
      Pages 533-551
    6. Charles Dearman, Ricky A. Sharma, Nicola J. Curtin
      Pages 553-579
  7. Back Matter
    Pages 581-591

About this book

Introduction

PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP—poly ADP ribose polymerase—in cancer therapy. The volume covers the history of the discovery of PARP and its role in DNA repair. Additionally, it describes the discovery of the PARP family, and includes a discussion of other DNA maintenance-associated PARPs. As well, the volume features a section on the accessible chemistry behind the development of inhibitors.

PARP inhibitors—PARPi—are a group of pharmacological inhibitors that are particularly good targets for cancer therapy. PARP plays a pivotal role in DNA repair and may contribute to the therapeutic resistance to DNA-damaging agents used to treat cancer. Researchers have learned a great deal about the biology of PARP and how tumor-specific defects in DNA repair can be exploited by PARPi. The “synthetic lethality” of PARPi is an exciting concept for cancer therapy, and has led to heightened activity in this area.

Keywords

DNA repair PARP cancer carcinogenesis drug resistance inhibitors

Editors and affiliations

  • Nicola J. Curtin
    • 1
  • Ricky A. Sharma
    • 2
  1. 1.Northern Institute for Cancer Research and Newcastle University Institute for Ageing Medical SchoolNewcastle UniversityNewcastle upon TyneUnited Kingdom
  2. 2.CRUK-MRC Oxford Institute for Radiation OncologyUniversity of OxfordOxfordUnited Kingdom

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-319-14151-0
  • Copyright Information Springer International Publishing Switzerland 2015
  • Publisher Name Humana Press, Cham
  • eBook Packages Medicine
  • Print ISBN 978-3-319-14150-3
  • Online ISBN 978-3-319-14151-0
  • Series Print ISSN 2196-9906
  • Series Online ISSN 2196-9914
  • Buy this book on publisher's site